Loading
Immunotherapy can trigger dangerous attacks on the gut, lungs or heart. Use blood, gut bacteria and genetic markers to spot who is at risk and act early.
Immune-related adverse events cause treatment discontinuation and death, and their management is reactive. Autoantibody profiles, HLA types, microbiome composition, baseline cytokines and early T-cell clonal expansion are each associated with specific toxicities in retrospective series. The proposal is a prospective biomarker cohort across checkpoint inhibitor indications to derive and validate a toxicity risk model, followed by trials of pre-emptive strategies (early steroid-sparing agents, microbiome modulation, intensified monitoring) in high-risk patients.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Immune-related adverse events (irAEs), Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Shares Immune-related adverse events (irAEs), No one can predict who responds to immunotherapy, Toxicity and quality of life are undervalued, Immune checkpoint inhibitors.
Shares Immune-related adverse events (irAEs), Ipilimumab, Toxicity and quality of life are undervalued, Pembrolizumab.
Shares Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials, Toxicity and quality of life are undervalued.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/